Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pre-fusion rsv f antigens

A pre-fusion, chimeric technology, applied in the direction of fusion peptides, viral antigen components, antiviral agents, etc., can solve the problem of not producing candidates

Inactive Publication Date: 2014-06-04
NOVARTIS AG
View PDF66 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, efforts to generate soluble, stabilized prefusion F subunit antigens have not yielded candidates suitable for testing in humans

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pre-fusion rsv f antigens
  • Pre-fusion rsv f antigens
  • Pre-fusion rsv f antigens

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0535] 1. Post-fusion structure and pre-fusion model

[0536] RSV F structure after fusion

[0537] A stable, non-aggregating soluble RSV F subunit antigen ( figure 1 ). This engineered F is efficiently expressed and easily purified. Electron micrographs of negatively stained samples show the formation of non-aggregated, uniform cane-shaped molecules, consistent with postfused F trimers ( figure 2 A). The engineered F trimer is stable, and the circular dichroism spectrum shows no obvious melting when the temperature is up to 95 °C ( figure 2 B and 2C).

[0538] The RSV F protein was crystallized, and its structure was determined by molecular substitution and three-fold non-crystallographic symmetry (NCS) averaging (Table 3 and image 3 ). The structure does not include the p27 fragment (peptide between the two furin sites, which is lost after cleavage), the fusion peptide, the transmembrane region and the cytoplasmic domain ( Figure 4 ).

[0539] Table 3. Crysta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

Description

[0001] related application [0002] This application claims priority to US Provisional Application 61 / 486,005, filed May 13, 2011. The entire contents of the aforementioned applications are incorporated herein by reference. [0003] sequence listing [0004] This application contains a Sequence Listing submitted in ASCII format via EFS-Web, which is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 11, 2012, is named PAT05457.txt and is 98,385 bytes in size. Background of the invention [0005] Respiratory syncytial virus (RSV) is an enveloped non-segmented negative-sense RNA virus in the genus Pneumovirus of the Paramyxoviridae family. It is the leading cause of bronchiolitis and pneumonia in children's first year of life. RSV also causes superinfections including severe lower respiratory disease, which can occur at any age, especially in the elderly or those with compromised hearts, lungs or immune systems. [0006] To infect a host cell,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/135
CPCA61K39/155C12N2760/18534C07K2319/735C12N2760/18522A61K2039/53C07K14/005A61K39/12A61P31/14
Inventor K·斯旺森A·卡尔菲
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com